Monopar Therapeutics
Price & Volume
Stats
See moreOpen | $62.01 |
Previous Close | $63.12 |
Day Range | $61.32-$62.73 |
52W Range | $28.40-$105 |
Market Cap | $422.8M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.93 |
News
See moreYahoo Finance • 7 days ago
Monopar's ALXN1840 Shows Significant Copper Reduction In Phase 2 Trial For Wilson Disease
Yahoo Finance • 12 days ago
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance • last month
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Yahoo Finance • 2 months ago
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
About
CEO | Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. |
CFO | Mr. Quan Anh Vu |
Address | 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 22 |